Literature DB >> 32479046

Suppressing Subcapsular Sinus Macrophages Enhances Transport of Nanovaccines to Lymph Node Follicles for Robust Humoral Immunity.

Yi-Nan Zhang1,2, Wilson Poon1,2, Elana Sefton1,2, Warren C W Chan1,2,3,4,5.   

Abstract

Nanovaccines need to be transported to lymph node follicles to induce humoral immunity and generate neutralizing antibodies. Here, we discovered that subcapsular sinus macrophages play a barrier role to prevent nanovaccines from accessing lymph node follicles. This is illustrated by measuring the humoral immune responses after removing or functionally altering these cells in the nanovaccine transport process. We achieved up to 60 times more antigen-specific antibody production after suppressing subcapsular sinus macrophages. The degree of the enhanced antibody production is dependent on the nanovaccine dose and size, formulation, and administration time. We further found that pharmacological agents that disrupt the macrophage uptake function can be considered as adjuvants in vaccine development. Immunizing mice using nanovaccines formulated with these agents can induce more than 30 times higher antigen-specific antibody production compared to nanovaccines alone. These findings suggest that altering transport barriers to enable more of the nanovaccine to be delivered to the lymph node follicles for neutralizing antibody production is an effective strategy to boost vaccination.

Entities:  

Keywords:  adjuvant; antibody; humoral immunity; lymph node; macrophage inhibitor; nanovaccine; subcapsular sinus macrophages

Mesh:

Substances:

Year:  2020        PMID: 32479046     DOI: 10.1021/acsnano.0c02240

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  8 in total

Review 1.  Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy.

Authors:  Michael P Vincent; Justin O Navidzadeh; Sharan Bobbala; Evan A Scott
Journal:  Cancer Cell       Date:  2022-02-10       Impact factor: 31.743

Review 2.  Innovations in lymph node targeting nanocarriers.

Authors:  Jihoon Kim; Paul A Archer; Susan N Thomas
Journal:  Semin Immunol       Date:  2021-11-24       Impact factor: 11.130

3.  Quantitation of lymphatic transport mechanism and barrier influences on lymph node-resident leukocyte access to lymph-borne macromolecules and drug delivery systems.

Authors:  Paul A Archer; Lauren F Sestito; Margaret P Manspeaker; Meghan J O'Melia; Nathan A Rohner; Alex Schudel; Yajun Mei; Susan N Thomas
Journal:  Drug Deliv Transl Res       Date:  2021-06-24       Impact factor: 4.617

4.  Enhancing subcutaneous injection and target tissue accumulation of nanoparticles via co-administration with macropinocytosis inhibitory nanoparticles (MiNP).

Authors:  Trevor Stack; Yugang Liu; Molly Frey; Sharan Bobbala; Michael Vincent; Evan Scott
Journal:  Nanoscale Horiz       Date:  2021-04-22       Impact factor: 10.989

Review 5.  Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.

Authors:  Ariel Isser; Natalie K Livingston; Jonathan P Schneck
Journal:  Biomaterials       Date:  2020-12-05       Impact factor: 15.304

Review 6.  Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.

Authors:  Ting Cai; Huina Liu; Shun Zhang; Jing Hu; Lingxiao Zhang
Journal:  J Nanobiotechnology       Date:  2021-11-25       Impact factor: 10.435

7.  Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.

Authors:  Yi-Nan Zhang; Jennifer Paynter; Cindy Sou; Tatiana Fourfouris; Ying Wang; Ciril Abraham; Timothy Ngo; Yi Zhang; Linling He; Jiang Zhu
Journal:  Sci Adv       Date:  2021-10-20       Impact factor: 14.136

Review 8.  Self-adjuvanting cancer nanovaccines.

Authors:  Zhiyun Liao; Jing Huang; Pui-Chi Lo; Jonathan F Lovell; Honglin Jin; Kunyu Yang
Journal:  J Nanobiotechnology       Date:  2022-07-26       Impact factor: 9.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.